









市場行情
/
股票
/
nasdaq-fate
/

Fate Therapeutics Inc

FATE

1.120USD

-0.030-2.61%

收盤 12/15, 16:00（美東）報價延遲15分鐘

129.18M總市值

虧損本益比TTM



Fate Therapeutics Inc

1.120

-0.030-2.61%

概覽公司財務分析

概覽

公司

財務

分析

關於 Fate Therapeutics Inc 公司

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.

Fate Therapeutics Inc簡介



公司代碼FATE

公司名稱Fate Therapeutics Inc

上市日期Oct 01, 2013

CEOValamehr (Bahram)

員工數量181

證券類型Ordinary Share

年結日Oct 01

公司地址12278 Scripps Summit Drive

城市SAN DIEGO

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編92131

電話18588751803

網址https://fatetherapeutics.com/

公司代碼FATE

上市日期Oct 01, 2013

CEOValamehr (Bahram)

Fate Therapeutics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. William H. (Bill) Rastetter, Ph.D.

Independent Chairman of the Board

617.42K

Mr. Kamal Adawi

Chief Financial Officer

75.00K

Dr. Bahram Valamehr, Ph.D.

President, Chief Executive Officer, Director

65.61K

-18.06%

Ms. Cindy R. Tahl, J.D.

Chief Legal and Compliance Officer, Corporate Secretary

58.39K

-13.40%

Dr. Robert S. (Rob) Epstein, M.D.

Independent Director

11.33K

Dr. Shefali Agarwal, M.D.

Independent Director

10.49K

Dr. Karin Jooss, Ph.D.

Independent Director

9.85K

Dr. Xu Yuan, Ph.D.

Independent Director

Mr. Michael Lee

Independent Director

Mr. Matthew C. Abernethy, CPA

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Dr. William H. (Bill) Rastetter, Ph.D.

Independent Chairman of the Board

617.42K

Mr. Kamal Adawi

Chief Financial Officer

75.00K

Dr. Bahram Valamehr, Ph.D.

President, Chief Executive Officer, Director

65.61K

-18.06%

Ms. Cindy R. Tahl, J.D.

Chief Legal and Compliance Officer, Corporate Secretary

58.39K

-13.40%

Dr. Robert S. (Rob) Epstein, M.D.

Independent Director

11.33K

Dr. Shefali Agarwal, M.D.

Independent Director

10.49K

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月18日週二

持股股東

股東類型

持股股東

佔比

Redmile Group, LLC

11.16%

ARK Investment Management LLC

8.94%

The Vanguard Group, Inc.

7.63%

BlackRock Institutional Trust Company, N.A.

7.36%

Wilshire Advisors LLC

7.36%

其他

57.56%

持股股東

佔比

Redmile Group, LLC

11.16%

ARK Investment Management LLC

8.94%

The Vanguard Group, Inc.

7.63%

BlackRock Institutional Trust Company, N.A.

7.36%

Wilshire Advisors LLC

7.36%

其他

57.56%

股東類型

持股股東

佔比

Investment Advisor/Hedge Fund

35.47%

Investment Advisor

29.79%

Hedge Fund

8.07%

Venture Capital

3.31%

Research Firm

2.58%

Individual Investor

1.52%

Pension Fund

0.13%

Family Office

0.12%

Bank and Trust

0.11%

其他

18.91%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

362

90.58M

121.91%

2025Q3

392

90.63M

123.83%

-62.33K

2025Q2

417

90.67M

126.20%

-17.10M

2025Q1

428

107.83M

118.91%

-28.45M

2024Q4

466

102.82M

135.16%

-13.40M

2024Q3

501

116.61M

140.28%

-7.11M

2024Q2

512

123.74M

135.30%

-845.14K

2024Q1

525

124.52M

115.54%

-6.97M

2023Q4

539

96.81M

133.02%

-789.66K

2023Q3

563

97.53M

144.16%

-13.48M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Redmile Group, LLC

12.88M

11.17%

+11.33K

+0.09%

Jul 02, 2025

ARK Investment Management LLC

10.31M

8.94%

+10.31M

Mar 31, 2025

The Vanguard Group, Inc.

8.77M

7.6%

-1.54M

-14.97%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

8.61M

7.47%

+225.50K

+2.69%

Jun 30, 2025

Johnson & Johnson Innovation-JJDC, Inc.

3.38M

2.93%

Jun 30, 2025

Acadian Asset Management LLC

2.46M

2.13%

-13.61K

-0.55%

Jun 30, 2025

Geode Capital Management, L.L.C.

2.43M

2.11%

+159.56K

+7.03%

Jun 30, 2025

Vestal Point Capital, LP

2.52M

2.18%

-850.00

-0.03%

Jun 30, 2025

State Street Investment Management (US)

2.23M

1.93%

+119.06K

+5.64%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Invesco NASDAQ Future Gen 200 ETF

0.7%

WisdomTree BioRevolution Fund

0.28%

iShares Micro-Cap ETF

0.03%

ProShares Ultra Nasdaq Biotechnology

0.02%

Invesco Nasdaq Biotechnology ETF

0.02%

iShares Russell 2000 Value ETF

0.01%

Global X Russell 2000 ETF

0.01%

Proshares Ultra Russell 2000

0.01%

iShares Biotechnology ETF

0.01%

Invesco RAFI US 1500 Small-Mid ETF

0.01%

Invesco NASDAQ Future Gen 200 ETF

佔比0.7%

WisdomTree BioRevolution Fund

佔比0.28%

iShares Micro-Cap ETF

佔比0.03%

ProShares Ultra Nasdaq Biotechnology

佔比0.02%

Invesco Nasdaq Biotechnology ETF

佔比0.02%

iShares Russell 2000 Value ETF

佔比0.01%

Global X Russell 2000 ETF

佔比0.01%

Proshares Ultra Russell 2000

佔比0.01%

iShares Biotechnology ETF

佔比0.01%

Invesco RAFI US 1500 Small-Mid ETF

佔比0.01%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Fate Therapeutics Inc的前五大股東是誰？



Fate Therapeutics Inc的前五大股東如下：
Redmile Group, LLC
持有股份：12.88M
佔總股份比例：11.17%。
ARK Investment Management LLC
持有股份：10.31M
佔總股份比例：8.94%。
The Vanguard Group, Inc.
持有股份：8.77M
佔總股份比例：7.60%。
BlackRock Institutional Trust Company, N.A.
持有股份：8.61M
佔總股份比例：7.47%。
Johnson & Johnson Innovation-JJDC, Inc.
持有股份：3.38M
佔總股份比例：2.93%。